Analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Down 5.4 %
Evoke Pharma stock opened at $0.53 on Wednesday. Evoke Pharma has a 52 week low of $0.52 and a 52 week high of $2.42. The stock has a market cap of $4.49 million, a P/E ratio of -0.23 and a beta of 0.22. The stock has a 50 day moving average of $0.65 and a 200-day moving average of $0.96.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last posted its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. The company had revenue of $1.68 million for the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative return on equity of 517.99%.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- Energy and Oil Stocks Explained
- 4 Golden Crosses With Double-Digit Upside Ahead
- What Investors Need to Know About Upcoming IPOs
- All-Aboard! Greenbrier Companies Breaks Out, New Highs Ahead
- What Does Downgrade Mean in Investing?
- 3 High Dividend Socks to Replace Lower Savings Yields Ahead
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
